Rivoceranib(a.k.a. Apatinib) is the first successful small-molecule tyrosine kinase inhibitor already approved to treat gastric cancer in China in December 2014. In US, Europe and South Korea, it has been granted orphan drug designation. The drug has been clinically tested with over 1,000 patients worldwide and has demonstrated its efficacy in numerous cancers including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors. Rivoceranib has also shown potential to significantly improve outcomes in combination treatment with chemotherapeutics and immunotherapy as well as for maintenance therapy.
Seclidemstat is a novel epigenetic oral small molecule for target therapy. It acts to normalize gene expression and suppress tumor growth via its highly selective and reversible inhibition of malfunctioned Lysine Specific Demethylase 1 (LSD 1) overexpressed in various solid tumors such as lung cancer, breast cancer, and prostate cancer.
Tegavivint is a potent and selective inhibitor of the Wnt/ß-catenin signaling pathway, implicated in cell proliferation, differentiation, and immune evasion. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types.